海曲泊帕联合用药治疗免疫性血小板减少症中的临床研究进展OA

Immune thrombocytopenia(ITP)is an acquired autoimmune disease involving multiple mechanisms,which leads to platelet destruction and macrocytosis and impaired platelet production,mainly manifested as decreased platelet levels and a tendency to bleed,which seriously affects the quality of life and prognosis of patients.Treatment of ITP aims to increase platelet count(PLT),reduce the incidence of fatal bleeding,and improve quality of life.To improve efficacy,reduce adverse reac-tions and the advent of thrombopoietin receptor agonists(TPO-RAs)prompted a shift in ITP treat-ment to combination therapy.Hetrombopag is a novel oral second generation small molecule,non-peptide TPO-RAs that binds to the transmembrane domain of thrombopoietin receptor(TPO-R),stimu-lates megakaryocyte proliferation and differentia-tion,and promotes platelet production.Hetrom-bopag combined with other drugs(glucocorticoid,rhTPO and cyclosporine A)in the treatment of ITP can achieve multi-target treatment,through the in-tegration of different drug mechanisms of action,can more comprehensively intervene in the patho-genesis of ITP,so as to improve the therapeutic ef-fect,so this article reviews the clinical research progress of hetrombopag combination in the treat-ment of ITP.